Last reviewed · How we verify

anti-MUC1 CAR-pNK cells

PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Phase 1 active Biologic

anti-MUC1 CAR-pNK cells is a Biologic drug developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. It is currently in Phase 1 development. Also known as: Chimeric antigen receptor NK cells with specificity for MUC1.

At a glance

Generic nameanti-MUC1 CAR-pNK cells
Also known asChimeric antigen receptor NK cells with specificity for MUC1
SponsorPersonGen BioTherapeutics (Suzhou) Co., Ltd.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about anti-MUC1 CAR-pNK cells

What is anti-MUC1 CAR-pNK cells?

anti-MUC1 CAR-pNK cells is a Biologic drug developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd..

Who makes anti-MUC1 CAR-pNK cells?

anti-MUC1 CAR-pNK cells is developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. (see full PersonGen BioTherapeutics (Suzhou) Co., Ltd. pipeline at /company/persongen-biotherapeutics-suzhou-co-ltd).

Is anti-MUC1 CAR-pNK cells also known as anything else?

anti-MUC1 CAR-pNK cells is also known as Chimeric antigen receptor NK cells with specificity for MUC1.

What development phase is anti-MUC1 CAR-pNK cells in?

anti-MUC1 CAR-pNK cells is in Phase 1.

Related